AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious Disease
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
AbCellera, a leader in therapeutic antibody discovery from natural immune systems, today announced it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic antibody candidates for infectious diseases. AbCellera will apply its expertise in single-cell screening of natural immune sources to generate rich panels of antibody candidates for evaluation by Gilead. Under the agreement, AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.
“AbCellera is dedicated to partnering with the most innovative companies to discover breakthrough therapies, and we look forward to adding our technology to Gilead’s early research efforts,” commented Carl Hansen, President and CEO of AbCellera.
Leveraging a suite of proprietary technologies, AbCellera’s team can interrogate millions of single B cells in a campaign, an approach that has proven successful in identifying low-frequency subsets of antibodies among large and diverse panels of binders. In this collaboration, AbCellera will be looking for ultra-rare antibodies with specific properties defined by Gilead, a challenging problem that demands screening depths that are orders of magnitude higher than alternative discovery approaches.
Over the past three years, AbCellera has successfully completed more than 30 antibody discovery programs, including deals with seven global pharmaceutical companies and top-tier public and venture-backed biotech companies. Applying best-in-class technology and custom innovation to each project, AbCellera enables programs for any target class, including difficult multi-pass membrane proteins, and provides its partners with a competitive advantage through superior diversity, speed, and quality.
“AbCellera is dedicated to partnering with the most innovative companies to discover breakthrough therapies, and we look forward to adding our technology to Gilead’s early research efforts,” commented Carl Hansen, President and CEO of AbCellera.
Leveraging a suite of proprietary technologies, AbCellera’s team can interrogate millions of single B cells in a campaign, an approach that has proven successful in identifying low-frequency subsets of antibodies among large and diverse panels of binders. In this collaboration, AbCellera will be looking for ultra-rare antibodies with specific properties defined by Gilead, a challenging problem that demands screening depths that are orders of magnitude higher than alternative discovery approaches.
Over the past three years, AbCellera has successfully completed more than 30 antibody discovery programs, including deals with seven global pharmaceutical companies and top-tier public and venture-backed biotech companies. Applying best-in-class technology and custom innovation to each project, AbCellera enables programs for any target class, including difficult multi-pass membrane proteins, and provides its partners with a competitive advantage through superior diversity, speed, and quality.
